Quality risk management (QRM) is a structured way to identify, assess, and control risks that could affect your peptide products. The main guideline for QRM is ICH Q9, which is accepted by regulators around the world.
If you are not using risk management in your peptide facility, you are behind the curve. Regulators expect it, and it makes your operations better.
- ICH Q9 provides a flexible framework for managing quality risks in peptide manufacturing without prescribing specific tools or methods.
- Focus risk assessments on high-impact areas like amino acid coupling, raw material control, and storage conditions to prevent costly failures.
- Use FMEA as your primary tool to systematically identify failure modes, assess severity, and prioritize corrective actions across production steps.
- Regulators expect genuine, data-supported risk assessments in submissions, not rubber-stamp exercises used to justify reducing controls or testing.
- Review and update risk assessments regularly, especially after process changes, deviations, or new regulatory guidance like the 2023 ICH Q9 revision.
- Build a risk-aware culture by training all staff on QRM principles so risk thinking becomes part of daily operations, not just documentation.
What Is ICH Q9?
ICH Q9 is a guideline published by the International Council for Harmonisation. It provides a framework for applying quality risk management principles to pharmaceutical manufacturing.
The guideline was first published in 2005 and revised in 2023. The revision added more emphasis on formality, decision-making, and the link between risk management and the pharmaceutical quality system.
ICH Q9 does not tell you exactly what to do. Instead, it gives you a framework and lets you choose the tools and methods that work best for your situation.
Why QRM Matters for Peptide Manufacturing
Peptide manufacturing involves many complex steps. Each step carries risks that could affect product quality.
Without a structured approach to managing these risks, you are reacting to problems instead of preventing them. QRM helps you focus your resources where they matter most.
According to the ICH Q9(R1) revision published in 2023, one of the key updates was the emphasis on avoiding "subjectivity" and "risk-based" justifications that are not properly supported by data and scientific knowledge. Regulators want to see genuine risk assessments, not rubber-stamp exercises.
The QRM Process
ICH Q9 outlines a simple process for managing risks. It has four main steps.
| Step | What You Do |
|---|---|
| Risk Assessment | Identify hazards and analyze risks |
| Risk Control | Decide what to do about the risks |
| Risk Review | Check that your controls are working |
| Risk Communication | Share risk information with stakeholders |
Step 1: Risk Assessment
Risk assessment is the foundation of QRM. It involves three sub-steps.
Risk Identification: What could go wrong? For peptide manufacturing, risks include contamination, incorrect amino acid coupling, degradation during storage, and many more.
Risk Analysis: How likely is it, and how bad could it be? Estimate the probability and severity of each risk.
Risk Evaluation: Is the risk acceptable? Compare the risk level to your predefined criteria. Decide if action is needed.
Step 2: Risk Control
Once you know your risks, you need to decide what to do about them. There are two approaches.
Risk Reduction: Take actions to lower the probability or severity of the risk. This might mean adding a quality control test, improving a process step, or upgrading equipment.
Risk Acceptance: If a risk is low enough, you may decide to accept it without further action. Document your rationale for accepting the risk.
Step 3: Risk Review
Risk management is not a one-time activity. Review your risks regularly to make sure your controls are still working.
Review risks when changes occur (new equipment, new processes, new regulations) and on a scheduled basis (at least annually).
Step 4: Risk Communication
Share risk information with everyone who needs to know. This includes your quality team, production staff, management, and regulators.
Good risk communication helps everyone understand why certain controls are in place. It also helps build a risk-aware culture.
"Quality risk management is not about creating perfect documents. It is about having meaningful conversations about what could go wrong and what we are doing to prevent it. The document is just the record of that conversation," says Dr. Martin Krieger, a pharmaceutical quality consultant specializing in ICH guidelines.
Common QRM Tools
ICH Q9 lists several tools you can use for risk assessment. Here are the most common ones used in peptide manufacturing.
Failure Mode and Effects Analysis (FMEA)
FMEA is the most widely used QRM tool in the pharmaceutical industry. It systematically evaluates each step of a process for potential failure modes.
For each failure mode, you rate three factors on a scale (usually 1 to 10).
| Factor | What It Measures |
|---|---|
| Severity (S) | How bad is the impact if it happens? |
| Occurrence (O) | How likely is it to happen? |
| Detection (D) | How likely are we to catch it before it causes harm? |
Multiply the three scores to get a Risk Priority Number (RPN). Higher RPNs indicate higher priority risks.
Hazard Analysis and Critical Control Points (HACCP)
HACCP identifies critical control points in your process where controls are essential. It was originally developed for the food industry but is useful for peptide manufacturing too.
HACCP is especially good for identifying contamination risks and critical process parameters.
Fault Tree Analysis (FTA)
FTA starts with a failure event and works backwards to identify all possible causes. It creates a visual diagram (the fault tree) showing the logical relationships between causes and effects.
FTA is useful for investigating complex failures in peptide manufacturing, such as a batch failure with multiple possible causes.
Risk Ranking and Filtering
This simpler tool involves listing risks and ranking them based on predefined criteria. It is useful for prioritizing a large number of risks quickly.
Applying QRM to Peptide Manufacturing
Here are some practical examples of how to apply QRM in a peptide facility.
Peptide Synthesis Process
Identify risks at each step of your synthesis process. Key risks include incomplete coupling reactions, side reactions, and racemization.
For each risk, determine what controls you have in place. These might include in-process testing, validated process parameters, and raw material specifications.
Raw Material Control
Raw materials are a major source of risk in peptide manufacturing. Assess the risks associated with each raw material, including quality variability, supply disruptions, and contamination.
Use risk ranking to prioritize which raw materials need the most rigorous controls. High-risk materials should have tighter specifications and more frequent testing.
Equipment and Facility
Assess risks related to equipment failure, cross-contamination, and facility design. Consider what would happen if a critical piece of equipment broke down during production.
For more on cross-contamination risks, see our article on cross-contamination prevention in GMP facilities.
QRM and Regulatory Submissions
Regulators expect to see evidence of QRM in your regulatory submissions. Risk assessments support many aspects of your filing.
Where QRM Appears in Submissions
- Process validation protocols (risk-based approach)
- Specifications (risk-based justification)
- Control strategy (linked to risk assessments)
- Stability protocols (risk-based design)
- Environmental monitoring programs (risk-based sampling)
Common QRM Mistakes
Many peptide facilities make the same mistakes when implementing QRM. Avoid these pitfalls.
- Treating risk assessment as a paperwork exercise rather than a real analysis
- Using subjective scoring without clear criteria
- Not revisiting risk assessments when things change
- Focusing only on obvious risks and missing less obvious ones
- Not involving the right people (include operators, not just managers)
- Setting all risks to "low" to avoid extra work
- Not linking risk assessments to actual process controls
Building a Risk-Aware Culture
QRM works best when it is part of your culture, not just a compliance exercise.
Train all employees on basic risk management concepts. Encourage them to speak up when they see potential risks.
Include risk discussions in your regular team meetings. Make it normal to talk about what could go wrong and how to prevent it.
For workforce development strategies, check out our industry trends for peptide professionals.
Frequently Asked Questions
Do I need a formal QRM program for FDA compliance?
Yes. While the FDA does not mandate a specific QRM tool, 21 CFR 211 and FDA guidance documents expect manufacturers to use risk-based approaches to quality management. ICH Q9 is the most widely accepted framework and is referenced in many FDA guidances.
How often should risk assessments be reviewed?
Risk assessments should be reviewed at least annually and whenever significant changes occur. Changes that should trigger a review include new equipment, process changes, new products, regulatory changes, and after any significant quality event like a product recall or major deviation.
What is the difference between ICH Q9 and ICH Q10?
ICH Q9 focuses specifically on quality risk management tools and processes. ICH Q10 describes the broader pharmaceutical quality system, which includes QRM as one of its key components. Both guidelines work together to support a comprehensive quality management approach.
How detailed does a risk assessment need to be?
The level of detail should match the level of risk. High-risk processes (like aseptic filling) need detailed FMEA or similar analysis. Lower-risk processes (like packaging) may only need a simple risk ranking exercise. The key is to be proportionate and justify your approach.
Can I use QRM to justify reducing testing or controls?
Yes, but carefully. QRM can support a science-based rationale for adjusting controls. However, you must have solid data to support your risk assessment. Regulators will scrutinize any reduction in controls, so make sure your justification is strong.
What training do people need for QRM?
At minimum, all quality and manufacturing staff should understand the basic principles of risk management. Team leads and quality professionals should be trained in specific QRM tools like FMEA. Consider formal training courses or certifications for your QRM champions.
Final Thoughts
Quality risk management is not just a regulatory requirement. It is a powerful tool for making better decisions about your peptide manufacturing operations.
Start with the areas of highest risk. Use the right tools for the job. Involve the right people, and revisit your assessments regularly.
When QRM becomes part of how you think and work, you will see fewer deviations, fewer audit findings, and better product quality. That benefits everyone, from your team to your patients.
Topics
Dr. Lisa Park
Regulatory Affairs Specialist
PharmD | 9 years in peptide pharmaceutical compliance
Focuses on FDA, DEA, and state pharmacy board regulations governing peptide compounds. Guides compounding pharmacies and peptide manufacturers through changing compliance landscapes.
Reviewed by Dr. Lisa Park, PharmD, April 2026